Read by QxMD icon Read

Fecal calprotectin

Lisette Binkhorst, Annemieke Sobels, Rogier Stuyt, Elsbeth M Westerman, Rachel L West
OBJECTIVE: Currently, a biosimilar of Remicade is available (CT-P13). Switching patients from Remicade to a biosimilar is still under debate, especially for patients with inflammatory bowel disease (IBD). In a retrospective study, we investigated the feasibility and safety of switching patients with IBD from Remicade to a biosimilar infliximab. PATIENTS AND METHODS: At two large general hospitals in The Netherlands, adult patients with a diagnosis of Crohn's disease or ulcerative colitis being treated with Remicade were asked to switch to the biosimilar infliximab (CT-P13)...
March 13, 2018: European Journal of Gastroenterology & Hepatology
Warapan Nakayuenyongsuk, Megan Christofferson, David K Stevenson, Karl Sylvester, Henry C Lee, K T Park
OBJECTIVE: To establish baseline trends in fecal calprotectin, a protein excreted into the stool when there is neutrophilic inflammation in the bowel, in infants at risk for necrotizing enterocolitis (NEC). STUDY DESIGN: We performed a prospective observational cohort study in infants with a birth weight of <1500 g without existing bowel disease at a level IV neonatal intensive care unit from October 2015 to September 2016. Stools were collected once daily for 30 days or until 32 weeks postmenstrual age and processed using the Fecal Calprotectin High Range Quantitative Quantum Blue assay...
March 6, 2018: Journal of Pediatrics
Heidi Kammerlander, Jan Nielsen, Jens Kjeldsen, Torben Knudsen, Kim Oren Gradel, Sonia Friedman, Bente Mertz Nørgård
Background: Fecal calprotectin (FC) is a biomarker used for assessing disease activity among IBD patients. Sparse knowledge exists as to whether FC correlates with clinical disease activity during pregnancy. Our aim was to assess FC and selected biomarkers in women with moderate-severe IBD and correlate them with clinical disease activity scores in pregnant women. Methods: We identified a nationwide cohort of 219 singleton pregnancies in women with moderate-severe disease (all treated with anti-tumor recrosis factor-α [anti-TNF-α] therapy during pregnancy), and we reviewed the medical records to extract clinical details and information on biomarkers...
February 28, 2018: Inflammatory Bowel Diseases
Inbar Nakar, Gili Focht, Peter Church, Thomas D Walters, Guila Abitbol, Sudha Anupindi, Laureline Berteloot, Jessie M Hulst, Frank Ruemmele, Daniel A Lemberg, Steven T Leach, Ruth Cytter, Mary-Louise Greer, Anne M Griffiths, Dan Turner
BACKGROUND & AIMS: Bowel healing is an important goal of therapy for patients with Crohn's disease (CD). Although there have been many studies of mucosal healing, transmural healing (in the bowel wall) has not been investigated in children. We analyzed data from the ImageKids study to determine associations among mucosal and transmural healing and levels of calprotectin and c-reactive protein in children with CD. METHODS: We collected data from a multi-center study designed to develop 2 magnetic resonance enterography (MRE)-based measures for children with CD (6-18 years old)...
March 1, 2018: Clinical Gastroenterology and Hepatology
Takayuki Yamamoto, Takahiro Shimoyama, Satoru Umegae, Koichi Matsumoto
Achieving endoscopic remission or decreasing the level of fecal biomarkers as an ideal therapeutic goal in ulcerative colitis has not been determined. This prospective study was to compare the clinical relevance of endoscopic score with fecal biomarkers for predicting relapse after clinical remission and mucosal healing (MH). One hundred and sixty-four patients who achieved clinical remission and MH (Mayo endoscopic subscore (MES) 0 or 1) were included. At entry, fecal samples were collected for the measurement of calprotectin, lactoferrin, and hemoglobin...
February 20, 2018: Clinical and Translational Gastroenterology
Juan Egea-Valenzuela, Begoña González Suárez, Cristian Sierra Bernal, José Francisco Juanmartiñena Fernández, Marisol Luján-Sanchís, Mileidis San Juan Acosta, Blanca Martínez Andrés, Vicente Pons Beltrán, Violeta Sastre Lozano, Cristina Carretero Ribón, Félix de Vera Almenar, Joaquín Sánchez Cuenca, Fernando Alberca de Las Parras, Cristina Rodríguez de Miguel, Julio Valle Muñoz, Ignacio Férnandez-Urién Sainz, Carolina Torres González, Pilar Borque Barrera, Enrique Pérez-Cuadrado Robles, Noelia Alonso Lázaro, Pilar Martínez García, César Prieto de Frías, Fernando Carballo Álvarez
BACKGROUND: Capsule endoscopy (CE) is the first-line investigation in cases of suspected Crohn's disease (CD) of the small bowel, but the factors associated with a higher diagnostic yield remain unclear. OBJECTIVE: Our aim is to develop and validate a scoring index to assess the risk of the patients in this setting on the basis of biomarkers. PATIENTS AND METHODS: Data on fecal calprotectin, C-reactive protein, and other biomarkers from a population of 124 patients with suspected CD of the small bowel studied by CE and included in a PhD study were used to build a scoring index...
February 27, 2018: European Journal of Gastroenterology & Hepatology
Wing Yan Mak, Anthony Buisson, Michael J Andersen, Donald Lei, Joel Pekow, Russell D Cohen, Stacy A Kahn, Bruno Pereira, David T Rubin
BACKGROUND: Persistent active endoscopic and histological inflammation is associated with poorer outcomes in ulcerative colitis (UC). Fecal calprotectin is a surrogate marker of endoscopic and histological remission. AIMS: To confirm the correlation between fecal calprotectin and endoscopic or histological disease activity and to define the optimal cutoff value to detect endoscopic and histological remission. METHODS: From a prospectively maintained database, we analyzed 61 UC patients who had fecal calprotectin measurement and endoscopy performed within 1 month...
February 22, 2018: Digestive Diseases and Sciences
Arno R Bourgonje, Julius Z H von Martels, Paul de Vos, Klaas Nico Faber, Gerard Dijkstra
BACKGROUND: Patient-reported symptoms and endoscopic disease activity do not correlate well in Crohn's disease (CD). This warrants the need for reliable biomarkers to early detect active intestinal inflammation. Currently, the fecal calprotectin level is the most commonly used biomarker for inflammatory activity in CD. However, the diagnostic accuracy of the fecal calprotectin level is not fully efficacious and diagnosis may be further improved by the identification of other biomarkers for active CD...
2018: PloS One
Nicholas A Kennedy, Christopher A Lamb, Susan H Berry, Alan W Walker, John Mansfield, Miles Parkes, Rachel Simpkins, Mark Tremelling, Sarah Nutland, Julian Parkhill, Chris Probert, Georgina L Hold, Charlie W Lees
Background/Aims: Current models of Crohn's disease (CD) describe an inappropriate immune response to gut microbiota in genetically susceptible individuals. NOD2 variants are strongly associated with development of CD, and NOD2 is part of the innate immune response to bacteria. This study aimed to identify differences in fecal microbiota in CD patients and non-IBD controls stratified by NOD2 genotype. Methods: Patients with CD and non-IBD controls of known NOD2 genotype were identified from patients in previous UK IBD genetics studies and the Cambridge bioresource (genotyped/phenotyped volunteers)...
February 15, 2018: Inflammatory Bowel Diseases
Cary G Sauer, Matthew S Loop, Suresh Venkateswaran, Vin Tangpricha, Thomas R Ziegler, Ashish Dhawan, Courtney McCall, Erin Bonkowski, David R Mack, Brendan Boyle, Anne M Griffiths, Neal S Leleiko, David J Keljo, James Markowitz, Susan S Baker, Joel Rosh, Robert N Baldassano, Sonia Davis, Shiven Patel, Jessie Wang, Alison Marquis, Krista L Spada, Subra Kugathasan, Thomas Walters, Jeffrey S Hyams, Lee A Denson
Background: Vitamin D regulates intestinal epithelial and immune functions, and vitamin D receptor deficiency increases the severity of murine colitis. Bioavailable 25-hydroxyvitamin D (25(OH)D) is available to target tissues and may be a driver of immune function. The aim is to evaluate the relationship of bioavailable 25(OH)D to the clinical expression of treatment naive pediatric ulcerative colitis (UC). Methods: The PROTECT (Predicting Response to Standardized Pediatric Colitis Therapy) study enrolled children ≤17 years newly diagnosed with UC...
February 15, 2018: Inflammatory Bowel Diseases
Gwenny M Fuhler, Janine van der Giessen, C Janneke van der Woude, Maikel P Peppelenbosch
No abstract text is available yet for this article.
February 15, 2018: Inflammatory Bowel Diseases
Romy M Heilmann, Nora Berghoff, Joanne Mansell, Niels Grützner, Nolie K Parnell, Corinne Gurtner, Jan S Suchodolski, Jörg M Steiner
BACKGROUND: Calprotectin is a marker of inflammation, but its clinical utility in dogs with chronic inflammatory enteropathies (CIE) is unknown. OBJECTIVE: Evaluation of fecal calprotectin in dogs with biopsy-confirmed CIE. ANIMALS: 127 dogs. METHODS: Prospective case-control study. Dogs were assigned a canine chronic enteropathy clinical activity index (CCECAI) score, and histologic lesions severity was assessed. Fecal calprotectin, fecal S100A12, and serum C-reactive protein (CRP) were measured...
February 20, 2018: Journal of Veterinary Internal Medicine
Andreas Schwiertz, Jörg Spiegel, Ulrich Dillmann, David Grundmann, Jan Bürmann, Klaus Faßbender, Karl-Herbert Schäfer, Marcus M Unger
BACKGROUND/OBJECTIVE: Intestinal inflammation and increased intestinal permeability (both possibly fueled by dysbiosis) have been suggested to be implicated in the multifactorial pathogenesis of Parkinson's disease (PD). The objective of the current study was to investigate whether fecal markers of inflammation and impaired intestinal barrier function corroborate this pathogenic aspect of PD. METHODS: In a case-control study, we quantitatively analyzed established fecal markers of intestinal inflammation (calprotectin and lactoferrin) and fecal markers of intestinal permeability (alpha-1-antitrypsin and zonulin) in PD patients (n = 34) and controls (n = 28, group-matched for age) by enzyme-linked immunosorbent assay...
February 12, 2018: Parkinsonism & related Disorders
Uri Kopylov, Michael Starr, Craig Watts, Serge Dionne, Marc Girardin, Ernest G Seidman
OBJECTIVE: Inflammatory bowel disease (IBD) is generally reported to be associated with spondylarthropathies (SpA) in 5%-15% of cases. Systematic colonoscopic assessment by protocol demonstrated mucosal inflammation characteristic of Crohn disease (CD) in up to one-third of patients with SpA. Video capsule endoscopy (CE) is a superior diagnostic tool to detect small bowel mucosal disease. Our study compared the accuracy of CE to standard colonoscopy for detection of inflammatory bowel lesions in patients with SpA, and to describe predictors of small bowel inflammation (SBI) in this cohort...
February 15, 2018: Journal of Rheumatology
Fei Sjöberg, Dilip Kumar Malipatlolla, Piyush Patel, Ulrica Wilderäng, Marie Kalm, Gunnar Steineck, Cecilia Bull
BACKGROUND AND PURPOSE: Traditionally, elastase has been used to study exocrine activity of the pancreas in patients with chronic pancreatitis and cystic fibrosis, and calprotectin as a marker for gut-wall inflammation in patients with inflammatory bowel disease. The aim of the study was to find out whether elastase and calprotectin could be used as inflammatory markers for radiation-induced gut wall injury of the distal bowel. MATERIAL AND METHODS: Adult male mice were exposed to two, three, or four fractions of 6 Gy or 8 Gy irradiation to the sigmoid and rectum of the large bowel, using a linear accelerator...
February 15, 2018: Acta Oncologica
Tenzin Choden, Rohan Mandaliya, Aline Charabaty, Mark C Mattar
Inflammatory bowel disease has a high prevalence in women of childbearing age and can have a significant impact on pregnancy, from conceiving to carrying the pregnancy. Active disease during pregnancy is known to have negative effects on pregnancy outcomes; therefore, careful monitoring during this period is an important but challenging aspect of care and is crucial as it affects important management decisions. Recent data seems to suggest that endoscopy is a relatively safe procedure during all trimesters of pregnancy...
February 6, 2018: World Journal of Gastrointestinal Pharmacology and Therapeutics
Youlian Zhou, Zhenjiang Zech Xu, Yan He, Yunsheng Yang, Le Liu, Qianyun Lin, Yuqiang Nie, Mingsong Li, Fachao Zhi, Side Liu, Amnon Amir, Antonio González, Anupriya Tripathi, Minhu Chen, Gary D Wu, Rob Knight, Hongwei Zhou, Ye Chen
Gut microbiota dysbiosis contributes to the onset and perpetuation of inflammatory bowel disease (IBD). Given that gut microbiotas vary across geography and ethnicity, it remains obscure whether any universal microbial signatures for IBD diagnosis and prognosis evaluation exist irrespective of populations. Here we profiled the fecal microbiota of a series of Chinese IBD patients and combined them with two Western IBD cohorts, PRISM and RISK, for meta-analyses. We found that the gut microbial alteration patterns in IBD are similar among Chinese and Westerners...
January 2018: MSystems
Doron Yablecovitch, Adi Lahat, Sandra Neuman, Nina Levhar, Benjamin Avidan, Shomron Ben-Horin, Rami Eliakim, Uri Kopylov
Background: Small-bowel capsule endoscopy (CE) is a prime modality for evaluation of the small bowel. The Lewis score (LS) and the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI) are validated endoscopic indices for quantification of small-bowel inflammation on CE. It is unclear whether these indexes are interchangeable for the evaluation of mucosal inflammation in established Crohn's disease (CD). The aim of this study was to compare the quantitative evaluation of small- bowel inflammation by LS and CECDAI...
2018: Therapeutic Advances in Gastroenterology
María José Moreno Martínez, Manuel José Moreno Ramos, Luis Francisco Linares Ferrando
OBJECTIVE: To assess the relationship between the increase of fecal calprotectin, anti-Saccharomyces cerevisiae antibodies (ASCA) and disease markers in a group of patients with spondyloarthritis. METHODS: We evaluated patients who were at least 18-years-old and met the Assessment in Spondyloarthritis International Society (ASAS) criteria for spondyloarthritis or the New York modified criteria. We analyzed activity criteria, physical function, analytical criteria (human leukocyte antigen [HLA] B27, fecal calprotectin, presence of ASCA, among others) and demographic data...
February 1, 2018: Reumatología Clinica
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"